Success Story: Advancing Precision Medicine in Breast Oncology—An NIW Approval for an Indian Chief Resident Physician
Client’s Testimonial:
“My experience working with Chen immigration team on my immigration process has been phenomenal. Their expertise in Green card matters, particularly with EB2 NIW and EB1 categories, is truly exceptional. They have an in-depth understanding of the nuances involved, especially for physicians, which made a significant difference in my case. Chen and the team were thorough, highly responsive, and never took shortcuts. They consistently delivered more than promised and ensured every step was handled with precision and care. Thanks to their guidance, my NIW application was filed smoothly and approved quickly after upgrading to Premium.
Because of this outstanding experience, I am moving forward with Chen and the team for my EB1 processing as well. Their professionalism and commitment have earned my complete trust, and I highly recommend them to anyone seeking reliable immigration support.”
On January 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Chief Resident Physician in the field of Breast Oncology (Approval Notice).
General Field: Breast Oncology
Position at the Time of Case Filing: Chief Resident Physician
Country of Origin: India
State of Residence at the Time of Case Filing: California
Approval Notice Date: January 9th, 2026
Processing Time: 2 months, 24 days (Premium Processing Upgrade Requested)
Case Summary:
Precision in cancer treatment is not just about saving lives; it is about preserving the quality of life. This success story features a chief resident physician from India whose research is transforming how clinicians manage breast cancer progression.
With an M.B.B.S. and extensive training in surgical oncology, she focuses on identifying specific genomic markers and tumor microenvironmental determinants. Her work addresses a critical dilemma in the medical community: distinguishing between high-risk patients who need immediate intervention and low-risk patients who can safely opt for non-surgical “watchful waiting”.
The client’s research is vital to the United States because it tackles the heavy burden of breast cancer while aiming to reduce unnecessary surgeries. By elucidating these biological drivers, her work not only facilitates the development of new immune-based treatments but also supports broader national health initiatives designed to improve patient outcomes and ensure equal access to effective care.
To support the National Interest Waiver (NIW) petition, the case highlighted her impressive objective credentials and the influence of her work. She has authored 15 peer-reviewed journal articles, 9 abstracts and 1 preprint, which had garnered 107 citations at the time of filing. Notably, one of her articles ranked in the top 1% of most-cited articles in Clinical Medicine for its publication year, demonstrating the high utility of her findings. Additionally, her research has been supported by major funding sources, including the National Cancer Institute and the University of California, San Francisco’s Resource Allocation Program, further validating its national significance.
North America Immigration Law Group (NAILG) successfully demonstrated that the client is well-positioned to advance this critical endeavor and that her work offers substantial benefits to the U.S. healthcare system. The petition emphasized that her contributions extend beyond her immediate employment, benefiting the wider academic and medical communities. As a result, the case was approved on January 9, 2026, in just 2 months and 24 days via Premium Processing, securing a path for this talented researcher to continue her impactful work in the United States.